Shenhong Qu

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 449 citations

Medicine, Oncology, Pharmacology +12

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen et al. · Nature Medicine · 2021 · 403 citations

Medicine, Oncology, Pharmacology +6

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Hai‐Qiang Mai, Qiuyan Chen, Dongping Chen et al. · JAMA · 2023 · 233 citations · Full text

Medicine, Oncology, Pharmacology +15

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Yunpeng Yang, Jianji Pan, Hui Wang et al. · Cancer Cell · 2023 · 215 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Yuanyuan Zhao, Yuxiang Ma, Aimin Zang et al. · Journal of Hematology & Oncology · 2023 · 50 citations · Full text

Pharmacy, Oncology, Pharmacology +17